Success Metrics

Clinical Success Rate
94.7%

Based on 143 completed trials

Completion Rate
95%(143/151)
Active Trials
1(1%)
Results Posted
29%(41 trials)
Terminated
8(5%)

Phase Distribution

Ph phase_2
36
21%
Ph phase_4
30
18%
Ph not_applicable
25
15%
Ph phase_3
35
21%
Ph phase_1
33
20%
Ph early_phase_1
1
1%

Phase Distribution

34

Early Stage

36

Mid Stage

65

Late Stage

Phase Distribution160 total trials
Early Phase 1First-in-human
1(0.6%)
Phase 1Safety & dosage
33(20.6%)
Phase 2Efficacy & side effects
36(22.5%)
Phase 3Large-scale testing
35(21.9%)
Phase 4Post-market surveillance
30(18.8%)
N/ANon-phased studies
25(15.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.5%

143 of 153 finished

Non-Completion Rate

6.5%

10 ended early

Currently Active

1

trials recruiting

Total Trials

168

all time

Status Distribution
Active(3)
Completed(143)
Terminated(10)
Other(12)

Detailed Status

Completed143
unknown11
Terminated8
Not yet recruiting2
Withdrawn2
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
168
Active
1
Success Rate
94.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.6%)
Phase 133 (20.6%)
Phase 236 (22.5%)
Phase 335 (21.9%)
Phase 430 (18.8%)
N/A25 (15.6%)

Trials by Status

not_yet_recruiting21%
completed14385%
suspended11%
recruiting11%
terminated85%
unknown117%
withdrawn21%

Recent Activity

Clinical Trials (168)

Showing 20 of 168 trialsScroll for more
NCT00115609Phase 3

Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)

Completed
NCT07482085Phase 3

Efavirenz for the Treatment of Creutzfeldt-Jakob Disease

Not Yet Recruiting
NCT07341672Phase 1

A Single-center, Randomized, Open-label, Parallel-design Clinical Study to Evaluate the Pharmacokinetic Effects of Itraconazole, Fluconazole or Efavirenz on a Single Dose of Clifutinib in Healthy Participants

Not Yet Recruiting
NCT05076682Phase 2

Reverse Triple Negative Immune Resistant Breast Cancer

Recruiting
NCT00042289

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed
NCT06797674Phase 1

A Study of the Effect Efavirenz on the Plasma Levels of MK-7602 in Healthy Participants (MK-7602-005)

Completed
NCT06914869Phase 1

Drug-Drug Interaction Potential of Mavorixafor

Completed
NCT05909644Phase 1

An Open-label DDI Study of Omaveloxolone in Healthy Subjects

Completed
NCT06698016Phase 1

A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

Completed
NCT01380080Phase 4

REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment

Completed
NCT02722421Phase 2

Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women

Completed
NCT05067439Phase 1

A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

Completed
NCT05995249Phase 1

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Completed
NCT01886404

EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients

Completed
NCT01789879Phase 2

A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy

Completed
NCT00350272Phase 2

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

Completed
NCT02475915Phase 1

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

Completed
NCT00775606Phase 4

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Terminated
NCT05330273Phase 1

Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz

Completed
NCT04459598Phase 1

A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

Completed

Drug Details

Intervention Type
DRUG
Total Trials
168